# IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

> **NCT06014528** · PHASE2 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 168 (estimated)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** IN10018
- **DRUG:** Placebo of IN10018
- **DRUG:** Pegylated Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT06014528
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-06
- **Primary completion:** 2026-12-24
- **Final completion:** 2026-12-24
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014528, "IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06014528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*